ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements
Kilitch Drugs (India) held its 34th Annual General Meeting on August 27, 2026, transacting four business resolutions including financial statement approval and director re-appointment.
Kilitch Drugs filed its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Rights Issue proceeds of Rs. 49.92 Crore.
Kilitch Drugs(I) Ltd reported revenue from operations of ₹44.9 Cr (+4.2% YoY) and net profit of ₹2 Cr (-13.0% YoY) for Q1 FY27.
Kilitch Drugs (India) Ltd has scheduled a board meeting for August 13, 2026. The board will consider and approve unaudited financial results for the June quarter.
Kilitch Drugs submitted its Annual Report for FY 2025-26 and the notice for the 34th Annual General Meeting to the stock exchanges.
Kilitch Drugs (India) Limited has re-appointed Arivind Kumar & Co. as its Cost Auditor for a 12-month term.
Kilitch Drugs (India) Ltd announced its 34th Annual General Meeting scheduled for August 27, 2026, along with relevant book closure dates. The board also re-appointed cost auditors.
Kilitch Drugs (India) Limited submitted its Annual Secretarial Compliance Report for the financial year 2026. This mandatory regulatory filing confirms the company's adherence to SEBI governance standards.
Kilitch Drugs (India) Ltd will hold a Board Meeting on May 15, 2026, to consider and approve audited standalone and consolidated financial results for the year ended March 31, 2026. The company's trading window remains closed until 48 hours after the results are disclosed.